IL-6 treatment increases the survival of retinal ganglion cells in vitro: The role of adenosine A1 receptor  by Perígolo-Vicente, Rafael et al.
Biochemical and Biophysical Research Communications 430 (2013) 512–518Contents lists available at SciVerse ScienceDirect
Biochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate /ybbrcIL-6 treatment increases the survival of retinal ganglion cells in vitro: The role
of adenosine A1 receptor
Rafael Perígolo-Vicente, Karen Ritt, Mariana Rodrigues Pereira, Patrícia Maria Mendonça Torres,
Roberto Paes-de-Carvalho, Elizabeth Giestal-de-Araujo ⇑
Departamento de Neurobiologia, Programa de Pós-Graduação em Neurociências, Instituto de Biologia, Universidade Federal Fluminense, Outeiro de São João Batista s/n, Niterói,
Rio de Janeiro CEP 24020-140, Brazila r t i c l e i n f o
Article history:
Received 21 November 2012
Available online 8 December 2012
Keywords:
pCREB
BDNF
Neuronal death
Retina
Cell culture
pTrkB0006-291X  2012 Elsevier Inc.
http://dx.doi.org/10.1016/j.bbrc.2012.12.004
⇑ Corresponding author.
E-mail address: egiestal@vm.uff.br (E. Giestal-de-A
Open access under the Elsevia b s t r a c t
IL-6 is a pleiotropic cytokine classically denominated pro-inﬂammatory. It has been already demon-
strated that IL-6 can increase the survival of retinal ganglion cells (RGC) in culture. In this work, we show
that the trophic effect of IL-6 is mediated by adenosine receptor (A1R) activation. The neutralization of
extracellular BDNF abolished the IL-6 effect and the treatment with IL-6 and CHA (an agonist of A1R)
modulated BDNF expression as well as pCREB and pTrkB levels.
 2012 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
In 1986 Tadamitsu Kishimoto discovered interleukin-6 (IL-6)
while searching for the molecule responsible for differentiation
and growth of B lymphocytes [1,2]. IL-6 belongs to the neuropoiet-
ic cytokine family, which also includes ciliary neurotrophic factor
(CNTF), leukemia inhibitory factor (LIF), oncostatin-M (OSM), inter-
leukin-11 (IL-11), cardiotropin-1 (CT-1), neurotrophin-1 (NNT-1),
interleukin-27 (IL-27), neuropoietin and B-cell-stimulating factor.
These molecules share a common signaling pathway that involves
a transmembrane glycoprotein of 130 kDa (GP130) [3–5].
The IL-6 effects occur through a speciﬁc binding protein, aIL-6R.
The binding of IL-6 to the a-receptor subunit induces the homodi-
merization of gp130 subunits followed by the activation of cyto-
plasmic kinases of the Janus (JAK) family [4]. The activation of
JAKs then leads to the stimulation of proteins from the STAT family
(STAT3 and STAT1) – a family of signals transducers and activators
of transcription [4]. STAT dimers translocate into the nucleus and
induce transcription of immediate early genes, such as junB, and
the rapid activation of a nuclear factor, termed acute-phase re-
sponse factor (APRF) [4,6].
IL-6 is produced by Th1 and Th2 cells, B cells, macrophages,
astrocytes, ﬁbroblasts, osteoblasts, keratinocytes, endothelial and
mesangial cells [7]. In the central nervous system (CNS) it is
synthesized mainly by microglial cells and astrocytes, but also byraujo).
er OA license. neurons [6,8,9]. IL-6 synthesis can be induced by a variety of
stimuli, but its major inducers are lipopolysaccharides (LPS),
interleukin-1 (IL-1) and tumor necrosis factor (TNF) [10].
Much attention has been focused on the functional role of IL-6
in the CNS [11]. It promotes the differentiation of oligodendrocytes
into mature oligodendrocytes and it induces the differentiation of
cortical precursor cells into astrocytes. IL-6 also stimulates the
activation of astrocytes and plays a role in the survival and differ-
entiation of peripheral and central neurons [9,12]. In PC12, IL-6 in-
duces the differentiation of these cells into a neuronal phenotype
and supports their survival under adverse conditions in culture
[13–15].
Previous work from our laboratory showed the trophic effect of
IL-6 on axotomized rat retinal ganglion cells (RGC) kept in culture
for 48 h [16]. Also it was shown that IL-6 protects RGC from an in-
crease in intraocular pressure, a condition associated to glaucoma
[17].
Adenosine regulates various physiological processes in several
tissues. One good example is the cardiovascular system where
adenosine is responsible for a decrease in blood pressure as a con-
sequence of vasodilatation [18]. In the CNS, adenosine regulates
neurotransmitter release, neuronal survival and differentiation
[19]. The adenosine receptors can regulate cAMP production by
the activation (A1 and A3 receptors) or the inhibition (A2a and
A2b receptors) of the enzyme adenylyl cyclase [20].
The inhibition of neurotransmitter release by A1 adenosine
receptor (A1R) activation appears to be mediated by the blockade
of Ca2+ channels or activation of K+ channels and hyperpolarization
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tection and facilitates the release of neurotransmitters [24,25].
Adenosine is a modulator of the inﬂammatory response due to
the balance between the production of pro-inﬂammatory and anti-
inﬂammatory cytokines [26]. The levels of extracellular adenosine
depend either on the amount of adenosine synthesized in the
extracellular compartment on the release of adenosine from the
intracellular compartment [27].
It has been shown that adenosine stimulates the release of IL-6
in different tissues [28–30]. Besides, Biber and co-workers showed
that IL-6 induces an increase in mRNA expression of A1R in the
brain [31]. More recently, Biber and co-workers showed that IL-6
treatment enhances the A1R-mediated signaling in the brain under
excitotoxic situations, contributing to an important decrease in
neuronal degeneration [32].
The aim of this work was to analyze the participation of aden-
osine A1R on the trophic effect of IL-6 on RGC. Our results show
that A1R are mediating the IL-6 effect on RGC survival. We also
found that IL-6 and A1R stimulate a common downstream path-
way involving BDNF and the transcription factor CREB.2. Materials
IL-6 and antibodies anti-IL-6 and anti-BDNF were purchased
from PeproTech (NJ, USA). Antibody anti-pCREB (Ser133) came
from Cell Signaling (MA, USA). Antibody anti-A1R was bought from
Millipore (MA, USA). Antibodies anti-actin and anti-p-TrkB and bo-
vine serum albumin (BSA) came from Santa Cruz (CA, USA). The
secondary antibody anti-rabbit came from Bio-Rad (CA, USA). Med-
ium 199, trypsin and fetal calf serum were purchased from Gibco
(MD, USA). Petri dishes were bought from TPP (Switzerland). Pen-
icillin G, streptomycin sulfate, L-glutamine, poly-L-ornithine, horse-
radish peroxidase (HRP), tetramethylbenzidine, sodium
nitroprusside, dimethylsulfoxide (DMSO), 8-cyclopentyl-1,3-dipro-
pylxanthine (DPCPX), adenosine deaminase and N(6)-cyclohexyl-
adenosine (CHA) were obtained from Sigma (MO, USA). K252a
and NBI were purchased from Enzo Life Sciences (Switzerland).
Materials used in Western blot experiments came from GE (CT-
USA) and Ponceau red and H2O2 were purchased from VETEC (Bra-
zil). Paraformaldehyde, glutaraldehyde, glycine and methanol were
bought from J.T.Baker (Phillipsburg, NJ, USA). Entellan was sup-
plied by Merck (Darmstadt, Germany).3. Methods
3.1. Retrograde labeling of retinal ganglion cells
Lister Hooded rats were anaesthetized by hypothermia within
the ﬁrst 24 h after birth and 1.0 lL of a 30% HRP solution in 2%
DMSO was injected into each superior colliculus. Afterwards, the
animals survived for 16 h before the procedures used for cell cul-
ture. This time lapse was necessary for the uptake and retrograde
transport of HRP to the soma of RGC. Procedures using animals
were approved by the local committee for animal care and exper-
imentation (CEPA-projects #00196-10).
3.2. Cell culture
Primary cultures were prepared using procedures described
elsewhere [17]. Brieﬂy, rats at postnatal day 1 were killed by
decapitation and their eyes were removed. The pigmented epithe-
lium and attached tissues were separated from the neural retina
in a calcium- and magnesium-free balanced salt solution (CMF)
containing 100 lg/mL streptomycin + 100 U/mL penicillin. The
retinae were incubated in CMF containing 0.1% trypsin for16 min at 37 C. The action of trypsin was stopped by adding cul-
ture medium with 5% of fetal calf serum (FCS). Tissue was then
resuspended in complete medium (culture medium supplemented
with 2 mM glutamine, 100 lg/mL streptomycin, 100 U/mL penicil-
lin and 5% FCS) and mechanically dissociated using a Pasteur
pipette. After, 1 mL of the cell suspension was added to culture
dishes, previously treated with poly-L-ornithine (50 lg/mL), at a
plating density of 105cells/cm2. After plating the cultures were
incubated in 1 mL of complete medium for 4 h to allow for the
attachment of cells to the substrate. Then, 1 mL of complete
medium or 1 mL of complete medium containing the drugs to
be tested was added to each Petri dish. Cultures were maintained
in a humidiﬁed atmosphere of 5% CO2 and 95% air at 37 C for dif-
ferent timeframes. We also tested the effect of the vehicles used
for drug dilution and concluded that they did not inﬂuence the
survival of RGC (data not shown).3.3. Identiﬁcation of RGC in culture
The presence of HRP in RGC was revealed according to the pro-
tocol of Mesulan [33]. The monolayers were ﬁxed after 4 or 48 h
in vitro with a mixture of 1% paraformaldehyde and 2% glutaralde-
hyde in 0.1 M sodium phosphate buffer (Karnovski solution) for
5 min, washed in phosphate buffer and then reacted with tetra-
methylbenzidine and H2O2. After reaction, the coverslips were
washed in 0.2 M acetate buffer, dehydrated by air drying, im-
mersed brieﬂy in xylene and mounted in Entellan.3.4. Presentation of data and statistical analysis
The number of RGC on each coverslip was evaluated by count-
ing 1/20 of the total area using an Olympus microscope at a mag-
niﬁcation of 400 under bright ﬁeld. These analyzes were
performed using a double-blind process to minimize the inﬂuence
of the researcher on the experimental results. As an internal con-
trol for the variable percentage of ganglion cells labeled with
HRP in distinct experiments, the number of labeled cells at 4 h in
culture was taken as 100% and the results were reported as per-
centage of control. All data were expressed as mean ± standard er-
ror of the mean from experiments performed in duplicate or
triplicate and each experiment was repeated at least three times.
The overall statistical signiﬁcance was ﬁrst obtained by one-way
analysis of variance (ANOVA). Statistical signiﬁcance of all pairs
of multiple groups of data was assessed by Newman–Keuls com-
parison test. A value of P < 0.001 was considered signiﬁcant.3.5. Western blot
Cells were ﬁrst scraped off the dishes in sample buffer and the
material boiled for 10 min. Total amount of protein in each sample
was determined using the Bradford reagent [34], with BSA as stan-
dard. Samples containing 60 lg protein were submitted to 10%
SDS–PAGE gel electrophoresis and the proteins transferred to PVDF
membranes which were incubated overnight with anti-A1R anti-
body (1:100), or anti-BDNF (1:3000), or anti-pCREB (1:5000) or
anti-pTrkB (1:400), washed, incubated with peroxidase-conjugated
anti-rabbit secondary antibody (1:10,000) and revealed by the
Luminata (Millipore) chemiluminescence. To load control after rev-
elation membranes were washed in TBS (pH 7.6), then incubated
with glycine 0.2 M (pH 2.2) to remove the unbound primary and
secondary antibodies. Quantitative analysis of blots was performed
by scanning images and using the computer program Scion Image
(Scion Corporation, MD, USA).
Fig. 1. (A) NBI blocks the effect of IL-6 on the survival of RGC. CT – Control; NBI (Nitrobenzyl ThioInosine) 10 nM – Inhibitor of Adenosine transporter), 50 ng/mL IL-6:
interleukin 6, (n = 4–7). (B) Adenosine Deaminase inhibits the IL-6 effect on the survival of RGC. CT – Control; ADA (Adenosine Deaminase) 0.5 U/mL, 50 ng/mL IL-6;
interleukin 6, (n = 7–10). (C) DPCPX blocks the effect of IL-6 on the survival of RGC. CT – Control; DPCPX (8-cyclopentyl-1,3-dipropylxanthine) 10 nM: Antagonist of
Adenosine A1 Receptor), 50 ng/mL IL-6: interleukin 6, (n = 6–8). (D) CHA induces an increase in RGC survival. CT – Control; CHA (N6-cyclohexyl adenosine) 1–100 nM –
Agonists of Adenosine A1 Receptor, (n = 6–8). All data are presented as mean ± SEM, P < 0.001 compared to control 48 h.
Fig. 2. (A) K252a blocks the effect of IL-6 on the survival of RGC. CT – Control. IL-6 50 ng/mL: IL-6: interleukin-6. K252a 50 nM: Antagonist of Trk receptors, (n = 6–9). (B) Anti-
BDNF blocks the effect of IL-6 on the survival of RGC. CT – Control. IL-6 50 ng/mL: interleukin-6. Antibody anti-BDNF 0.125 lg/mL (n = 4–7). (C) Anti-BDNF blocks the effect of
CHA on the survival of RGC. CT – Control. CHA 1 nM: Adenosine A1 Receptor Agonist. Antibody anti-BDNF 0.125 lg/mL (n = 5–11). All data are presented as mean ± SEM,
P < 0.001 compared to control 48 h.
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Fig. 3. (A) BDNF levels in cultures treated with IL-6 for 45 min. CT – Control. IL-6 50 ng/mL: interleukin-6. (B) BDNF levels in cultures treated with IL-6 for 4 h. CT – Control.
IL-6 50 ng/mL: interleukin-6. (C) BDNF levels in cultures treated with IL-6 for 24 h. CT – Control. IL-6 50 ng/mL: interleukin-6. (D) BDNF levels in cultures treated with IL-6 for
48 h. CT – Control. IL-6 50 ng/mL: interleukin-6. (E) BDNF levels in cultures treated with CHA for 48 h. CT – Control. CHA 1 nM: A1 Adenosine Receptor Agonist. (F) Levels of
pTrkB in cultures treated with IL-6 for 48 h. Control. IL-6 50 ng/mL: interleukin-6. (G) BDNF treatment for 48 h downregulates BDNF levels. CT – Control. BDNF 50 ng/mL. All
data are presented as mean ± SEM (n = 3), P < 0.001 compared to CT.
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4.1. Adenosine is important to IL-6 effect
Fig. 1A shows that treatment with IL-6 (50 ng/mL) for 48 h in-
duces a signiﬁcant increase in the survival of RGC (65% when
compared to the 48 h control cultures). However, when cultures
were incubated with 10 nM NBI (an adenosine transporter inhibi-
tor) the effect of IL-6 was abolished, suggesting that adenosine
trafﬁc is necessary for the trophic effect of IL-6 on RGC. Corroborat-
ing this idea, when we treated cells for 48 h with 0.25 U/mL aden-
osine deaminase (ADA) the IL-6 effect on RGC survival was
inhibited (Fig. 1B). Together those results suggest that the presence
of adenosine in the extracellular space is necessary for the trophic
effect elicited by IL-6 on RGC.
4.2. Involvement of A1 adenosine receptors in the trophic effect of IL-6
Following we investigated the involvement of A1R in the IL-6
effect. Results presented in Fig. 1C show that treatment with an
antagonist of A1R (10 nM DPCPX) abolished the trophic effect of
IL-6. Accordingly, treating the cultures with the A1R agonist CHA
(1 and 10 nM), showed an increase in RGC survival. The stronger
effect (100% survival) was observed with 1 nM CHA and no effect
was observed using 100 nM CHA (Fig. 1D).
4.3. BDNF is involved in the IL-6 effect
Fig. 2A shows that treatment with 50 nM K252a (a selective
antagonist of Trk receptor) inhibited the IL-6 effect on RGC sur-
vival. Based on this result we evaluated whether BDNF was in-
volved in IL-6 effect using an anti-BDNF antibody. Fig. 2B shows
that the presence of anti-BDNF inhibited the IL-6 effect. To assess
whether BDNF was also involved in the CHA effect we treated cells
with anti-BDNF antibody in the presence of CHA. Fig. 2C demon-
strates that CHA effect was also abolished in the presence of
anti-BDNF.
4.4. Treatment with IL-6 or CHA modulates BDNF levels in retinal cell
cultures
Fig. 3A shows that treatment with IL-6 for 45 min increased
(94.6%) BDNF levels, although treatment of IL-6 for 4 or 24 h
(Fig. 3B–D) did not change BDNF levels and 48 h of IL-6 stimulus
downregulated (50% decrease) BDNF levels (Fig. 3D). Fig. 3E shows
a similar effect (56% decrease) when cells were treated with CHA
for 48 h. We then evaluated the levels of pTrkB receptor after treat-
ment with IL-6 for 48 h. Fig. 3F shows that in the presence of IL-6Fig. 4. (A) Levels of pCREB (pCREB) in cultures treated with IL-6 for 4 h. Control. IL-6 50 n
cultures treated with IL-6 for 48 h. Control. IL-6 50 ng/mL: interleukin-6. Data are presethe pTrkB levels decreased. We also analyzed the BDNF capacity to
downregulate its own levels. Fig. 3G shows that a 48 h BDNF treat-
ment, similarly to IL-6 stimulus, decreased BDNF levels.4.5. Treatment with IL-6 for 48 h decreases CREB phosphorylation
As CREB is an important transcriptional factor involved in BDNF
synthesis [37] we evaluated the levels of pCREB after 4 and 48 h of
IL-6 treatment. Fig. 4A shows that after 4 h of IL-6 treatment no
changes were observed in the pCREB levels. On the other hand,
when the cells were chronically exposed to IL-6 (48 h) we observed
(Fig. 4B) a decrease of about 50% in pCREB levels.5. Discussion
In the present work we show that adenosine and the activation
of A1R mediate the trophic effect of IL-6 on RGC. It has been al-
ready demonstrated that IL-6 treatment decreases the excitability
of post-synaptic transmission, due to an increase in the A1R activa-
tion, with a beneﬁcial impact on neuronal survival [32]. Our pres-
ent results are consistent with those ﬁndings since treatment with
DPCPX (A1R antagonist) abolished the IL-6 effect while treatment
with CHA (A1R agonist) induced an increase in RGC survival. Taken
together, our results conﬁrm the involvement of A1Rs in the IL-6
effect as previously demonstrated in other biological systems
[31,32].
In 2001, we showed that the IL-6 effect depended on the release
of vesicular polypeptides, since treatment with brefeldin A blocked
the IL-6 trophic effect [16]. This evidence suggests that IL-6 trophic
effect can be mediated by another molecule. It is already known
that neurotrophins are involved in survival pathways. For this rea-
son we investigated the participation of Trk receptors on the effect
of IL-6 on RGC survival and observed the suppression of IL-6 effect
when these receptors were blocked.
Studies show that in different experimental systems the effect
of IL-6 are correlated to neurotrophins [35,36] and it has been
demonstrated that IL-6 can modulate BDNF synthesis in different
experimental models [35,37,38]. Accordingly, our data show that
when BDNF action was blocked by neutralizing antibodies the ef-
fect of either IL-6 or CHA on the survival of RGC was abolished,
demonstrating the involvement of BDNF in the IL-6 effect.
To investigate if IL-6 was regulating the synthesis of BDNF we
analyzed by Western blot the levels of this neurotrophin after dif-
ferent time intervals of IL-6 treatment. The results show that IL-6
increases BDNF levels after 45 min of stimulus but not after 4 or
24 h. After 48 h of either IL-6 or CHA treatment we observed a
decrease in BDNF levels. Interestingly, 48 h of BDNF treatmentg/mL: interleukin-6. Data are presented as mean ± SEM (n = 3). (B) Levels of pCREB in
nted as mean ± SEM (n = 3).
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BDNF to downregulate its own levels.
The relationship between TrkB receptor phosphorylation and
the survival effects of BDNF in neuronal cells is well known [39].
To better understand the IL-6 effect on the control of BDNF levels,
we investigated the levels of pTrkB in our cultures after IL-6 treat-
ment. Our results show that the levels of pTrkB decreased after
treatment with IL-6 for 48 h. These results are in accordance with
our above mentioned results which show that BDNF levels are de-
creased after 48 h of IL-6 treatment.
The role of CREB (cAMP responsive element-binding protein) as
a transcription factor mediating BDNF synthesis is well established
[40]. We have found a decrease of pCREB levels after 48 h treat-
ment with IL-6. This result is in disagreement with that observed
by Murphy and co-workers after treatment of dorsal root ganglion
neurons with IL-6 [38]. These contradictory results could be ex-
plained by the differences between retinal cells and the cells pres-
ent in the dorsal root ganglia.
The death of RGC is observed in several important diseases such
as glaucoma or diabetes and is responsible for the blindness ob-
served in patients [17,41]. For this reason it is important to study
mechanisms involved in RGC survival in order to establish appro-
priate pharmacological protocols capable of increasing the survival
of these central neurons. Data from literature shows that IL-6 is
able to rescue RGC from death induced by high pressure condition
[17]. However, it is not easy to use IL-6 as a treatment since this
molecule can act like a pro-inﬂammatory cytokine inducing side
effects such as fever and even cell death [42–44]. In the present
work, we demonstrate that the trophic effect of IL-6 on RGC is
mediated by the activation of A1R. Given that A1R ligands are al-
ready widely used to treat different pathological conditions
[45,46] the use of A1R agonists might lead to a new therapeutic
strategy in diseases involving the death of RGC.
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